Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2023-06-16 Report Publication Anno…
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting, but it is not the presentation material itself. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Since this is a notice for an IR event, it fits best under RNS as a general regulatory announcement.
2023-06-16 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청)(EU103(항VSIG4 항체치료제) 고형엄 대상 제1상 임상시험계획서(IND) 변경승인신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for an amendment to a clinical trial plan (IND). This type of disclosure is a standard regulatory announcement for public companies in Korea to inform shareholders of material developments in their business operations, specifically clinical trials. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2023-05-23 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Eutilex' (주식회사 유틸렉스) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, management analysis, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
기타경영사항(자율공시)(돌연변이 EGFR 타겟의 키메라 항원 수용체 국내 특허권 취득)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) by Eutilex regarding the acquisition of a domestic patent for a chimeric antigen receptor targeting mutant EGFR. It details the patent's purpose, technical specifications, and future commercialization plans. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, M&A, or other specific categories, it is classified as a general regulatory filing.
2023-05-10 Korean
기타경영사항(자율공시)(돌연변이 EGFR 및 EphA2 동시 타겟하는 키메라 항원 수용체 국내 특허권 취득)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eutilex regarding the acquisition of a domestic patent for a chimeric antigen receptor targeting mutant EGFR and EphA2. It is categorized as a 'Regulatory Filing' (RNS) because it is a voluntary disclosure of a corporate event (patent acquisition) that does not fit into specific categories like M&A, financial reports, or director dealings.
2023-05-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically a sale of shares) by an executive (Kim Young-ho) of Eutilex. This type of filing is a standard regulatory requirement for insider trading/shareholding changes by company directors, which corresponds to the 'Director's Dealing' category.
2023-04-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.